Comparison
BPC-157 vs. GHRP-6
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Growth
CAS no.
137525-51-0
87616-84-0
Molecular weight
1419.5 g/mol
873.02 g/mol
Half-life
4 h
0.4 h
Sequence
GEPPPGKPADDAGLVHis-D-Trp-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
GHRP-6
GHRP-6 is a high-affinity agonist of the growth-hormone secretagogue receptor 1a (GHSR-1a) — the same receptor later shown to bind the endogenous hormone ghrelin. The identification of GHRP-6 as a pharmacological anchor led to cloning of GHSR in 1996 and the discovery of ghrelin itself in 1999. GHRP-6 stimulates pituitary GH secretion via a pathway independent of GHRH and can be combined synergistically with GHRH. Via GHSR in the hypothalamus it additionally activates NPY/AgRP neurons, producing an orexigenic (appetite-stimulating) effect in animal models.
Evidence base
Highest evidence
Animal model
Human trial
Studies
4
4
of which in humans
0
2
Effects recorded
4
4
Open conflicts
2
1
Documented adverse events
2
2